Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ: OCUL) fell short of the market’s revenue expectations in Q3 2026, with revenue falling 11.5% year on year to $12.87 million. Its GAAP loss of $0.42 per share was 16.1% below analysts’ consensus estimates.

For more on Ocular Therapeutix, read our full research report for free.

Dr. Dugel concluded, “With the competitive landscape evolving, AXPAXLI is now the only intravitreal sustained release maintenance agent with positive Phase 3 data in wet AMD. We believe our opportunity to fundamentally transform the treatment paradigm has never been greater. As such, we are rapidly advancing our commercial readiness, including the addition of Dr. Riad Sherif to our Board of Directors, who brings extensive global commercial experience in ophthalmology at Alcon, Novartis, Sanofi, and Oculis. We continue to progress our diabetic retinopathy program in parallel, as we work expeditiously toward bringing AXPAXLI to patients who urgently need more durable treatment options as quickly as possible.”

Revenue growth

Examining a company’s long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Ocular Therapeutix’s revenue grew at a mediocre 5.5% compounded annual growth rate over the last five years, falling short of the healthcare sector standard.

Long-term growth matters the most, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Ocular Therapeutix’s performance shows it grew in the past but relinquished its gains over the last two years, as its revenue fell by 9.4% annually.

This quarter, Ocular Therapeutix missed Wall Street’s consensus estimates and reported an uninspiring 11.5% year-on-year revenue decline, generating $12.87 million of revenue.

Looking ahead, sell-side analysts expect revenue to grow 50.2% over the next 12 months, according to S&P, an improvement versus the last two years. This strong projection suggests its newer products and services will drive better revenue performance.

Adjusted operating margin

Ocular Therapeutix’s high expenses have contributed to an average adjusted operating margin of negative 325% over the last five years. Unprofitable healthcare companies require extra attention because downturns can expose their financial vulnerabilities. It’s hard to be confident that the business can endure a full cycle.

Analyzing the trend in its profitability, Ocular Therapeutix’s adjusted operating margin decreased significantly over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 451 percentage points. This performance was poor, showing that its expenses were rising and it couldn’t pass those costs on to its customers.

Ocular Therapeutix’s adjusted operating margin was negative 760% this quarter. The company’s consistent lack of profits raises concerns.

Earnings per share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share, or EPS, points to the profitability of that growth. For example, a company could inflate its revenue through excessive spending on advertising and promotions.

Ocular Therapeutix’s losses deepened over the last five years as its EPS dropped 3.1% annually. Falling EPS warrants caution, as diminishing earnings could imply changing secular trends and preferences. If conditions change unexpectedly, Ocular Therapeutix’s low margin of safety could leave its stock price susceptible to large declines.

In Q3, Ocular Therapeutix reported EPS of negative $0.42, down from negative $0.38 in the same quarter last year. The result missed analysts’ consensus estimates. Over the next 12 months, Wall Street expects Ocular Therapeutix’s full-year EPS to stay about the same, moving from negative $1.46 to negative $1.45, according to S&P.

Key takeaways from Ocular Therapeutix’s Q3 results

Ocular Therapeutix delivered a softer quarter with few positives: Revenue missed expectations, and EPS also fell short of Wall Street’s consensus estimates. Shares tumbled 7.4% to $6.11 immediately after the report.

Ocular Therapeutix underperformed this quarter. When deciding whether to invest, it’s important to consider its valuation and business quality as well as the latest results. Read the full research report here (it’s free).